As the saying goes, "Time heals all." at least for some of the most innovative biotechs this is true. After 3 years of runs in CAR-T, cancer vaccines, and new immune checkpoint inhibitors, clincal companies have seemingly peaked in value. Immunology, the old favorite of the biotech horde has been out of favor as early as Q1 2015 and non-oncology based biopharmas have seen a rise in interest from the biotech flash boys. Today's ineresting plays and recent gainers have been in other specialized areas of disease.